DUBLIN – Syncona Ltd., the listed London-based biotech investment firm, is doubling down on gene therapy by investing $35 million in two new ventures, Swanbio Therapeutics Ltd., a Boston-based startup focused on central nervous system conditions, and Orbit Biomedical Ltd., a London-based firm developing a cannula device to enhance surgical delivery of gene therapy vectors to the back of the eye.